Corporate

Feb, 2019

News / Corporate

Feb 20, 2019

Astellas and WiserCare Announce Collaboration to Improve Patient Experience

Astellas US LLC and WiserCare, a company that develops healthcare decision support solutions, announced today a new collaboration focused on improving patient experience by eliciting and...

News / Corporate

Feb 11, 2019

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today results from the Phase 3 ARCHES trial in men with metastatic...

Dec, 2018

News / Corporate

Dec 20, 2018

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating XTANDI® (enzalutamide)...

News / Corporate

Dec 14, 2018

Astellas Acquires Potenza Therapeutics

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it exercised, and closed on its exclusive option to acquire Potenza Therapeutics, Inc....

News / Corporate

Dec 12, 2018

Astellas Promotes Lei Ding to vice president, Payer Strategy, Contracts, and Pricing

Astellas today announced that Lei Ding has been promoted to vice president, Payer Strategy, Contracts and Pricing. In this role, Ding will be responsible for leading these areas within Astellas'...